Provided herein are methods for the treatment in a subject of anemia anemia requiring RBC transfusion low or intermediate 1 risk myelodysplastic syndromes (MDS) and/or non proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin ActRII signaling inhibitors to a subject in need of the treatment.